Heart Failure With Preserved Ejection Fraction: Clinical Trials

16 trials for Heart Failure With Preserved Ejection Fraction, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 2 active not recruiting, 2 recruiting, 2 terminated. 16 Phase 3, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 316Completed 8, Active not recruiting 2, Recruiting 2, Terminated 2, Unknown 1, Withdrawn 1
Phase 25Completed 4, Unknown 1

Follow Heart Failure With Preserved Ejection Fraction: new trials by email Literature Review of Heart Failure With Preserved Ejection Fraction trials Research Report on Heart Failure With Preserved Ejection Fraction

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Maridebart cafraglutide, Placebo - Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction
Phase 3RecruitingAmgen50562025-06-252026-10-29
A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction
Low calorie meal replacement plan, Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy, Transthoracic echocardiography - Heart Failure With Preserved Ejection Fraction, Heart Failure, Diastolic
Phase 2 / Phase 3CompletedUniversity of Leicester662023-12-052026-07-22
The Effect of Addition of Metformin to SGLT2 In Diabetic Patients With Heart Failure With Preserved Ejection Fraction
Metformin - Heart Failure With Preserved Ejection Fraction, Diabete Type 2
Phase 2 / Phase 3UnknownOctober University for Modern Sciences and Arts802023-11-012023-10-12
Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation
Enavogliflozin, Placebo - Tricuspid Regurgitation, Heart Failure With Preserved Ejection Fraction
Phase 3Active not recruitingAsan Medical Center5412023-10-252025-12-29
A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure
Pulmonary arterial denervation, Guideline-directed medical therapy (GDMT) for heart failure - Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction
Phase 3Active not recruitingPulnovo Medical (Wuxi) Co., Ltd.2642023-08-142026-07-21
Dapagliflozin With or Without Spironolactone for HFpEF
Dapagliflozin, Spironolactone + Dapagliflozin - Heart Failure With Preserved Ejection Fraction
Phase 2 / Phase 3CompletedUniversidade do Porto1082022-09-152025-08-17
Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)
Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric], Placebo - Iron-deficiency, Heart Failure With Preserved Ejection Fraction
Phase 2 / Phase 3CompletedMassachusetts General Hospital652021-11-262026-09-04
Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
AZD4831, Placebo - Heart Failure With Preserved Ejection Fraction
Phase 2 / Phase 3CompletedAstraZeneca7112021-06-302025-08-27
Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction
Sacubitril-Valsartan - Heart Failure With Preserved Ejection Fraction
Phase 3WithdrawnFlinders University2020-02-012021-08-30
Spironolactone in the Treatment of Heart Failure
Experimental: Spironolactone, Placebo Comparator - Heart Failure with Mid-range Ejection Fraction, Heart Failure with Preserved Ejection Fraction
Phase 3TerminatedCharite University, Berlin, Germany7432018-11-012025-03-28
Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
Dapagliflozin, Placebo - Heart Failure With Preserved Ejection Fraction
Phase 3CompletedAstraZeneca62632018-08-272023-07-11
Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction
Spironolactone, Standard care - Heart Failure With Preserved Ejection Fraction
Phase 3RecruitingUppsala University20002017-11-232024-10-22
A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
sacubitril/valsartan, Enalapril, Valsartan - Heart Failure With Preserved Ejection Fraction
Phase 3CompletedNovartis Pharmaceuticals25722017-08-222021-10-11
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction
Oral treprostinil, Placebo - Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Phase 3TerminatedUnited Therapeutics842017-08-152020-11-10
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
LCZ696, Valsartan - Heart Failure With Preserved Ejection Fraction
Phase 3CompletedNovartis Pharmaceuticals48222014-07-182020-09-29
Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure
Enalapril, placebo - Heart Failure With Preserved Ejection Fraction, Heart Failure, Congestive
Phase 3CompletedWake Forest University712003-07-012017-11-06

Narrower conditions

Heart Failure (7)  ·  Cardiovascular Diseases (2)  ·  Diabetes Mellitus, Type 2 (2)  ·  Heart Failure, Diastolic (2)  ·  Hypertension, Pulmonary (2)  ·  Obesity (2)  ·  Anemia, Iron-Deficiency (1)  ·  Hypertension (1)  ·  Iron Deficiencies (1)  ·  Tricuspid Valve Insufficiency (1)  ·  Vascular Diseases (1)

Broader conditions

Heart Diseases (9)  ·  Cardiovascular Diseases (8)  ·  Nutritional and Metabolic Diseases (4)  ·  Metabolic Diseases (3)  ·  Body Weight (2)  ·  Diabetes Mellitus (2)  ·  Endocrine System Diseases (2)  ·  Glucose Metabolism Disorders (2)  ·  Lung Diseases (2)  ·  Nutrition Disorders (2)  ·  Overnutrition (2)  ·  Overweight (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Respiratory Tract Diseases (2)  ·  Signs and Symptoms (2)

Interventions

Valsartan (3)  ·  sacubitril and valsartan sodium hydrate drug combination (3)  ·  Enalapril (2)  ·  Spironolactone (2)  ·  dapagliflozin (2)  ·  AZD4831 (1)  ·  Diagnostic Imaging (1)  ·  Diet (1)  ·  Echocardiography (1)  ·  Electrocardiography (1)  ·  Enavogliflozin (1)  ·  Hematologic Tests (1)  ·  Metformin (1)  ·  Positron-Emission Tomography (1)  ·  Saline Solution (1)

Sponsors

AstraZeneca (2)  ·  Novartis Pharmaceuticals (2)  ·  Amgen (1)  ·  Asan Medical Center (1)  ·  Charite University, Berlin, Germany (1)  ·  Flinders University (1)  ·  Massachusetts General Hospital (1)  ·  October University for Modern Sciences and Arts (1)  ·  Pulnovo Medical (Wuxi) Co., Ltd. (1)  ·  United Therapeutics (1)  ·  Universidade do Porto (1)  ·  University of Leicester (1)  ·  Uppsala University (1)  ·  Wake Forest University (1)

Countries

United States (8)  ·  Netherlands (6)  ·  Belgium (5)  ·  Brazil (5)  ·  Bulgaria (5)  ·  Canada (5)  ·  Czechia (5)  ·  France (5)  ·  Hungary (5)  ·  Argentina (4)  ·  Austria (4)  ·  China (4)  ·  Denmark (4)  ·  Germany (4)  ·  Japan (4)

Top investigators

Adelino Leite-Moreira, MD, PhD (1)  ·  Bertram Pitt (1)  ·  Burkert Pieske, Prof. MD (1)  ·  Carmine De Pasquale, Assoc Prof (1)  ·  Dalane W Kitzman, MD (1)  ·  David Kaye, Professor (1)  ·  Gerry P McCann, MD (1)  ·  Greg Lewis, MD (1)  ·  Lars H Lund, MD, PhD (1)  ·  Majo Joseph, Doctor (1)

Results publications

PMID 42669134, PMID 25415957, PMID 28662936, PMID 29890892, PMID 29980595, PMID 31081589, PMID 31302043, PMID 31475794, PMID 31726194, PMID 31736337, PMID 31736342, PMID 31806129, PMID 32192799, PMID 32241619, PMID 32731928, PMID 32845715, PMID 33189633, PMID 33714741, PMID 33727901, PMID 33839075, PMID 33866828, PMID 33888245, PMID 33998278, PMID 34097449, PMID 34392331, PMID 34693515, PMID 34783839, PMID 34796742, PMID 34807713, PMID 34918855, PMID 35241246, PMID 35483796, PMID 35603665, PMID 35603667, PMID 35717169, PMID 35895867, PMID 36027570, PMID 36029465, PMID 36029467, PMID 36041668, PMID 36041669, PMID 36041912, PMID 36050227, PMID 36100197, PMID 36114137, PMID 36189985, PMID 36190011, PMID 36326604, PMID 36372069, PMID 36522606

NIH funding

2016 (1), 2018 (1), R01HL151841 (1), U01HL134679 (1), U01HL134694 (1)